non-arteritic ischemic optic neuropathy
Conditions
Interventions
experimental group:anisodine hydrobromide and regular treatment
control group:regular treatment
Sponsors
The First Medical Center of Chinese PLA General Hospilal
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. After inquiring the history of disease and injury, the patient was confirmed as NAION by visual acuity, fundus, visual field, fundus fluorescence angiography, etc.; 2. The course of illness is less than 1 month; 3. Patients aged 18-80 years, regardless of gender, and aged patients were determined by researchers; 4. Visual acuity >= 0.05.
Exclusion criteria
Exclusion criteria: 1. Patients with other serious eye diseases that affect visual function, such as glaucoma, corneal inflammation and turbidity, uveitis and obvious clouding of the lens, diabetic proliferative retinopathy, ischemic neuropathy in the anterior temporal artery inflammation, macular hole, retinal detachment, retinitis pigmentosa, etc.; 2. Patients with hemorrhagic diseases and acute cerebral hemorrhage; 3. Severe heart disease, severe arrhythmia or heart failure; 4. Severe abnormal liver and kidney functions; 5. Allergic constitution, so as to know allergy to two or more drugs or food; or are known to be allergic to the ingredients; 6. Women who are already pregnant, have a pregnancy plan or are breastfeeding; 7. The investigator determined that the patients were not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment of 1, 2, 3, 6 months of the total effective rate of the disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment for visual changes at 1, 2, 3 and 6 months;Changes in visual field at 1, 2, 3 and 6 months after treatment;Optic disc edema, optic disc perfusion and macular area perfusion; | — |
Countries
China
Contacts
Public ContactWei Shihui
Chinese PLA General Hospilal
Outcome results
None listed